SCHEMBL316936

SCHEMBL316936

O=C(O)c1cc(Cl)c(F)c(-c2ccccc2)n1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CA P42336 1/20 0.46
PTGER1 P34995 4/20 0.45
DHODH Q02127 1/20 0.42
KMO O15229 3/20 0.41
MCL1 Q07820 2/20 0.41
KDM4E B2RXH2 2/20 0.41
ALOX15 P16050 1/20 0.41
TSHR P16473 1/20 0.41
ACMSD Q8TDX5 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
ALDH1A1 P00352 2/20 0.41
NPC1 O15118 1/20 0.41
GAA P10253 1/20 0.41
HPGD P15428 1/20 0.41
RAB9A P51151 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
GPR35 Q9HC97 1/20 0.41
CNR1 P21554 1/20 0.40
MDM2 Q00987 1/20 0.40
RPA1 P27694 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15439882 0.83 PIK3CA (0.48) PIK3CAPTGER1DHODHKMOMCL1
SCHEMBL16698002 0.76 KDM4E (0.52) PIK3CAPTGER1DHODHKMOKDM4E
SCHEMBL27793098 0.76 MAPT (0.44) PTGER1DHODHMCL1KDM4EALDH1A1
SCHEMBL28658361 0.74 ECE1 (0.41) KMOKDM4EALOX15RAB9AGPR35
SCHEMBL319073 0.73 KDM4E (0.52) PTGER1DHODHKMOKDM4EALOX15
SCHEMBL15440719 0.72 XDH (0.41) PTGER1DHODHKDM4EALDH1A1NPC1
SCHEMBL15440485 0.72 XDH (0.44) PIK3CAPTGER1DHODHKDM4EACMSD
SCHEMBL15439892 0.72 CDH1 (0.49) PTGER1DHODHKMOMCL1SMN1; SMN2
SCHEMBL10985563 0.71 KDM4E (0.48) PTGER1DHODHMCL1KDM4EALOX15
SCHEMBL15449377 0.71 ALDH1A1 (0.41) DHODHKDM4EALDH1A1NPC1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2081903-B1 2-AMINOCARBONYL-PYRIDINE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2014-05-07 EP disclosed
US-8093250-B2 2-aminocarbonyl-pyridine derivatives ACTELION PHARMACEUTICALS LTD. (CH) 2012-01-10 US disclosed
US-20100035895-A1 2-AMINOCARBONYL-PYRIDINE DERIVATIVES ACTELION PHARMACEUTICALS LTD. (CH) 2010-02-11 US disclosed
EP-2081903-A2 2-AMINOCARBONYL-PYRIDINE DERIVATIVES Actelion Pharmaceuticals Ltd. (CH) 2009-07-29 EP disclosed
WO-2008044217-A2 2-AMINOCARBONYL-PYRIDINE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2008-04-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100035895-A1 2-AMINOCARBONYL-PYRIDINE DERIVATIVES P2RY12, P2RY2, P2RY1 PIK3CA 227/4885PTGER1 56/4885DHODH 3075/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.